3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
NET
1
Head & Neck
1
Gastrointestinal
1
Endocrine
1
Conditions
Thyroid Neoplasms
3
Thoracic Neoplasms
2
Respiratory Tract Neoplasms
2
Respiratory Tract Diseases
2
Neoplasms, Nerve Tissue
2
Neoplasms, Germ Cell and Embryonal
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Neoplasms
2
Lung Neoplasms
2
Lung Diseases
2
Head and Neck Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Bronchogenic
2
Carcinoma
2
Adenocarcinoma
2
Thyroid Diseases
1
Thyroid Cancer, Papillary
1
Neuroendocrine Tumors
1
Neuroectodermal Tumors
1
Neoplasms, Glandular and Epithelial
1
Multiple Endocrine Neoplasia Type 2a
1
Locally Advanced Thyroid Gland Carcinoma
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Endocrine System Diseases
1
Endocrine Gland Neoplasms
1
Digestive System Neoplasms
1
Interventions
selpercatinib
3
Sorafenib
3
cabozantinib
2
Thyroid (USP)
2
Sodium
2
Radiofrequency Ablation
2
Metformin
2
Data Collection
2
vandetanib
1
tomivosertib
1
temsirolimus
1
repotrectinib
1
pralsetinib
1
pembrolizumab
1
lenvatinib
1
binimetinib
1
apatinib
1
acetaminophen, codeine drug combination
1
Watchful Waiting
1
Vitamin B 12
1
Tramadol
1
Thyroxine
1
Thyrotropin-Releasing Hormone
1
Thyroidectomy
1
Technetium Tc 99m Sestamibi
1
Surgical Procedures, Operative
1
Pemetrexed
1
Panobinostat
1
Observation
1
Negative-Pressure Wound Therapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Thyroid Diseases
×
pralsetinib
×
Head & Neck
×
Clear all
NCT03037385
2025-05-31
ARROW
Hoffmann-La Roche
Phase 1/2
Completed
590 enrolled
58 charts
3 FDA